Focus

New Covid lab development ready for next step

Fanshawe’s Centre for Research and Innovation announces a new laboratory development that can speed up validation of effectiveness for potential Covid-19 treatments

FANSHAWE COLLEGE’S CENTRE for Research and Innovation has developed a safe, rapid and inexpensive method to identify the effectiveness of potential Covid-19 drug treatments.

Principal investigator Abdulla Mahboob, PhD in biotechnology with experience in the biochemistry of RNA viruses, has developed artificial copies of the SARS-COV-2 virus called ‘replicons’ that can be transferred into mammalian cells.

“We are ready to work with a commercial partner who can actively participate in this venture to take our proof-of-concept success from our small college lab to large-scale application” ―Abdulla Mahboob

The replicons are non-infectious, containing all the non-structural genes of the virus, but missing the genes allowing the virus to assemble into an infectious agent. This enables testing of new COVID-19 drug therapies against the replicon outside of the more expensive biosafety level-2 laboratories.

Fanshawe’s replicon has also been developed with two problematic mutations in the current pandemic: one that is associated with higher mortality and another that is resistant against the current treatment Remdesivir. Any pharmaceutical company would be able to use the lab-created replicons to rapidly screen a library of potential drug treatments for effectiveness against Covid-19.

Story Continues Below

“We are ready to work with a commercial partner who can actively participate in this venture to take our proof-of-concept success from our small college lab to large-scale application,” says Mahboob. “Our development, called the ‘Flexicon’, can make treatment testing much faster and more accessible to many labs around the world.”

Mahboob’s team is simultaneously working with the National Institutes of Health in the United States to validate a peptide-inhibitor treatment option for Covid-19.

“The faster we can effectively test the latest treatment options, the better our chances of potentially saving lives,” adds Mahboob.

Recent Posts

The four-day workweek isn’t dead. It’s just a secret

Some workers are stealthily taking three-day weekends — every weekend

4 hours ago

Even the pope is a bad boss

A first-ever Vatican employee satisfaction survey reveals distrust of managers and a workplace lacking initiative and collaboration. Sound familiar?

1 day ago

London Inc. Weekly

London Inc. Weekly: A summary of regional business news from the past week

4 days ago

Dispatch

Dispatch: A summary of recent business appointments and announcements, plus upcoming events for the week ahead

4 days ago

Does your workplace need a ‘crying room’?

A CBC North lawsuit puts the spotlight on how employers manage distress and psychological health

6 days ago

How to watch the 2026 World Cup in Canada: Stadiums, betting apps & live TV

The 2026 World Cup represents a landmark moment for Canadian football, both on and off the pitch

6 days ago